Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy
Interleukin-2 Imaging as a Guide to Cancer Immunotherapy (Ipilimumab or Pembrolizumab) in Advanced Melanoma: A Pilot Study
Sponsor: Mayo Clinic
This EARLY_PHASE1 trial investigates Stage IV Skin Melanoma and is currently completed. Mayo Clinic leads this study, which shows 9 recorded versions since 2014 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed EARLY_PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed EARLY_PHASE1
-
Sep 2019 — Jan 2021 [monthly]
Completed EARLY_PHASE1
Phase: NA → EARLY_PHASE1
-
May 2019 — Sep 2019 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
▶ Show 4 earlier versions
-
Jun 2018 — May 2019 [monthly]
Active Not Recruiting NA
-
Jun 2017 — Jun 2018 [monthly]
Active Not Recruiting NA
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting NA
First recorded
Mar 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mayo Clinic
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .